Navigating Challenges In Drug Repurposing For Parkinson's Disease: Comprehensive Review

Drug repurposing (DR) is a novel strategy to drug discovery that aims to uncover new applications for existing drugs. This technique is gaining popularity because to its cost-effectiveness and capacity to speed up the development process by employing molecules with proven pharmacokinetic and pharmacodynamic properties. In recent years, pharmaceutical companies have increasingly turned to DR, particularly for complicated disorders such as Parkinson's disease (PD). However, DR has significant problems in PD, such as illness complexity, diagnostic difficulty, regulatory impediments, and patient variety. The multidimensional nature of PD, which includes hereditary, environmental, and biological components, makes it challenging to create effective treatments. Misdiagnosis of PD and atypical parkinsonism syndromes hinders treatment. Regulatory difficulties and the short patent life of repurposed pharmaceuticals diminish pharmaceutical companies' incentives to invest in DR. The need for additional study into the underlying causes of PD, combined with problems in clinical trials and access to neurological services, and stymies progress. To address these problems, governments, foundations, and the pharmaceutical sector must collaborate on novel development paths, regulatory incentives, and drug repurposing for Parkinson's disease and other neurodegenerative disorders.